198 related articles for article (PubMed ID: 9062144)
1. Continuous low-dose combined hormone replacement therapy and the risk of endometrial cancer.
Comerci JT; Fields AL; Runowicz CD; Goldberg GL
Gynecol Oncol; 1997 Mar; 64(3):425-30. PubMed ID: 9062144
[TBL] [Abstract][Full Text] [Related]
2. Hormone replacement therapy and cancer.
Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
[TBL] [Abstract][Full Text] [Related]
3. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
Genazzani AR; Gadducci A; Gambacciani M
Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
[TBL] [Abstract][Full Text] [Related]
4. Hormone replacement therapy in postmenopausal women.
Yasui T; Uemura H; Takikawa M; Irahara M
J Med Invest; 2003 Aug; 50(3-4):136-45. PubMed ID: 13678382
[TBL] [Abstract][Full Text] [Related]
5. Dose of progestin in postmenopausal-combined hormone therapy and risk of endometrial cancer.
Reed SD; Voigt LF; Beresford SA; Hill DA; Doherty JA; Weiss NS
Am J Obstet Gynecol; 2004 Oct; 191(4):1146-51. PubMed ID: 15507934
[TBL] [Abstract][Full Text] [Related]
6. Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women.
Gambacciani M; Ciaponi M; Cappagli B; Genazzani AR
Am J Obstet Gynecol; 2001 Nov; 185(5):1180-5. PubMed ID: 11717654
[TBL] [Abstract][Full Text] [Related]
7. Mammographic breast density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low-potency estrogen regimens.
Lundström E; Wilczek B; von Palffy Z; Söderqvist G; von Schoultz B
Climacteric; 2001 Mar; 4(1):42-8. PubMed ID: 11379377
[TBL] [Abstract][Full Text] [Related]
8. Low-dose hormone replacement therapy: effects on bone.
Gambacciani M; Monteleone P; Genazzani AR
Climacteric; 2002 Jun; 5(2):135-9. PubMed ID: 12051108
[TBL] [Abstract][Full Text] [Related]
9. Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy.
McGonigle KF; Karlan BY; Barbuto DA; Leuchter RS; Lagasse LD; Judd HL
Gynecol Oncol; 1994 Oct; 55(1):126-32. PubMed ID: 7959253
[TBL] [Abstract][Full Text] [Related]
10. ACOG Committee Opinion No. 420, November 2008: hormone therapy and heart disease.
American College of Obstetricians and Gynecologists Committee on Gynecologic Practice
Obstet Gynecol; 2008 Nov; 112(5):1189-92. PubMed ID: 18978127
[TBL] [Abstract][Full Text] [Related]
11. Endometrial cancer and hormone-replacement therapy in the Million Women Study.
Beral V; Bull D; Reeves G;
Lancet; 2005 Apr 30-May 6; 365(9470):1543-51. PubMed ID: 15866308
[TBL] [Abstract][Full Text] [Related]
12. Continuous HRT with oestrogen plus progestogen is linked to reduced risk of endometrial cancer.
Mayor S
BMJ; 2015 Dec; 351():h6627. PubMed ID: 26645093
[No Abstract] [Full Text] [Related]
13. Regulation of estrogen/progestogen receptors in the endometrium.
Casper RF
Int J Fertil Menopausal Stud; 1996; 41(1):16-21. PubMed ID: 8673152
[TBL] [Abstract][Full Text] [Related]
14. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer.
Strom BL; Schinnar R; Weber AL; Bunin G; Berlin JA; Baumgarten M; DeMichele A; Rubin SC; Berlin M; Troxel AB; Rebbeck TR
Am J Epidemiol; 2006 Oct; 164(8):775-86. PubMed ID: 16997897
[TBL] [Abstract][Full Text] [Related]
15. Protecting the endometrium. Opposing the hyperplasia/malignancy potential of ERT.
Gibbons WE; Thorneycroft IH
J Reprod Med; 1999 Feb; 44(2 Suppl):203-8. PubMed ID: 11392033
[TBL] [Abstract][Full Text] [Related]
16. Hormone replacement therapy and endometrial cancer risk: a meta-analysis.
Grady D; Gebretsadik T; Kerlikowske K; Ernster V; Petitti D
Obstet Gynecol; 1995 Feb; 85(2):304-13. PubMed ID: 7824251
[TBL] [Abstract][Full Text] [Related]
17. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy.
Simon JA; Liu JH; Speroff L; Shumel BS; Symons JP
Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201
[TBL] [Abstract][Full Text] [Related]
18. [Hormone replacement therapy and the risk of developing breast cancer].
Merz WE
MMW Fortschr Med; 2004 Feb; 146(9):26-8, 30. PubMed ID: 15352702
[TBL] [Abstract][Full Text] [Related]
19. Hormone replacement therapy and endometrial cancer.
Emons G; Huschmand-Nia A; Krauss T; Hinney B
Onkologie; 2004 Apr; 27(2):207-10. PubMed ID: 15138357
[TBL] [Abstract][Full Text] [Related]
20. Hormone replacement therapy and estrogen-dependent cancers.
Birkhäuser M
Int J Fertil Menopausal Stud; 1994; 39 Suppl 2():99-114. PubMed ID: 7874193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
